From diapers to drugs: How India’s global corporate hubs are putting AI to work

Reuters reports Global Capability Centres in India are increasingly deploying AI across marketing, finance, HR, and operations, with examples spanning Microsoft, Apollo Hospitals, Catalyst Brands, Kimberly-Clark, Novo Nordisk, IBM, and Workday. The article highlights efficiency gains such as 20% of doctors' time being returned through an AI clinical assistant and faster regulatory, safety, and commercial analytics workflows. The tone is constructive for enterprise software and AI adoption, but the piece is largely thematic and unlikely to move markets on its own.

Analysis

The market is underestimating how quickly AI adoption inside multinational operating hubs can turn into margin leverage, not just headline-friendly productivity. The first beneficiaries are the software and infrastructure layers that get embedded into repeatable enterprise workflows: Microsoft as the default orchestration stack, Workday where AI can reduce back-office labor intensity, and IBM where services-led AI integration can turn into higher-value consulting pull-through. The second-order winner is India as a delivery base: once AI tools compress cycle times in finance, HR, regulatory, and marketing, GCCs become less about cheap labor and more about scalable execution capacity, which should support budget expansion rather than headcount growth.

Healthcare and pharma have the most visible near-term monetization path because AI directly shortens time-to-decision in regulated workflows. That creates a meaningful gap between revenue impact and cost savings: the immediate P&L upside is in fewer hours and faster submissions, while the longer-duration upside is improved launch cadence and better trial throughput. For Novo Nordisk, Amgen, and AstraZeneca, the real edge is not lower SG&A alone; it is faster iteration in launch execution and pharmacovigilance, which can extend exclusivity-period economics by bringing products forward even a few weeks in a high-value indication.

The consumer angle is more nuanced. Kimberly-Clark and retailer-facing organizations can use AI to cut content production costs and improve influencer selection, but the bigger effect may be competitive pressure on smaller brands and agencies that relied on manual campaign execution. If AI-generated imagery materially reduces the need for photo shoots and physical inventory movement, that is a structural advantage for scaled incumbents with centralized data and weaker for niche players that sell brand storytelling more than product utility.

The contrarian view is that the market may be too focused on cost takeout and not enough on reinvestment: every efficiency gain raises the probability that managements redeploy savings into more AI spend, cloud consumption, and enterprise software. That means the near-term earnings uplift could be partially offset by higher vendor budgets, but the winners still skew toward the platforms that become indispensable. The main risk is implementation drag: if AI pilots remain siloed and fail to integrate with core workflows over the next 6-12 months, enthusiasm could fade quickly and the narrative revert to 'promised productivity, delayed returns.'

Key Decisions for Investors

• Long MSFT vs. short a basket of legacy IT-services names over 3-6 months: Microsoft should capture the highest share of enterprise AI workflow spend; risk is valuation if monetization stays back-half weighted.
• Long WDAY into the next 1-2 quarters on the thesis that AI-driven payroll/hiring automation expands seat stickiness and raises switching costs; use a tight stop if enterprise software budgets soften.
• Long IBM on a 6-12 month horizon as the 'picks-and-shovels' beneficiary of AI implementation in regulated workflows; reward is services mix improvement, but upside is capped if consulting demand broadens slowly.
• Pair long KMB / short a smaller branded-consumer peer that lacks internal AI scale, targeting 3-6 months: KMB should see better marketing efficiency and lower content-production costs; downside is limited if consumer volumes weaken broadly.
• For healthcare, prefer long NVO or AMGN on dips over the next 6 months as AI improves launch and safety workflows; the trade works best if management commentary begins quantifying cycle-time savings, but execution risk remains high.